Pharmacotherapy for human immunodeficiency virus-associated nephropathy

Pharmacotherapy

Volumn 25, Issue 12 I, 2005, Pages 1761-1772

  Pope, Scott D ^a   Johnson, Melissa D ^b,c   May, D Byron ^b,c  

^a CAROLINAS MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Campbell University   (United States)

Author keywords

ACE inhibitors; Aids associated nephropathy; Chronic kidney failure; Corticosteroids; Cyclosporine; HAART; Highly active antiretroviral therapy; HIV; Kidney diseases

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOSINOPRIL; FUROSEMIDE; LISINOPRIL;

ADULT; AFRICA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG POTENCY; ENZYME INHIBITION; FEMALE; GLOMERULUS FILTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; MALE; PATIENT MONITORING; PROTEINURIA; REVIEW;

AIDS-ASSOCIATED NEPHROPATHY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS; CYCLOSPORINE; GLUCOCORTICOIDS; HUMANS;

EID: 29044444075     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.12.1761     Document Type: Review

References (75)

1. Winston JA, Klolman PE. Are we missing an epidemic of HIV-associated nephropathy? J Am Soc Nephrol 1996;7:1-7.
2. Swartz EJ, Szczech LA, Winston JA, Klotman PE. Effect of HAART on HIV-associated nephropathy [absir]. J Am Soc Nephrol 2000;11:165a.
3. Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 2001;33:115-19.
4. Kimmel PL. The nephropathies of HIV infection: pathogenesis and treatment. Curr Opin Nephrol Hypertens 2000;9:117-22.
5. D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998;18: 406-21.
6. Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDs 2000;14:637-45.
7. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-85.
8. Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmentai glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:669-73.
9. Bird JE, Durham SK, Giancarli MR, et al. Captopril prevents nephropathy in HIV-transgenic mice. J Am Soc Nephrol 1998;9:1441-7.
10. Ahuja TS, Borucki M, Fumanilla M, Shahinian V, Hollander M, Rajaraman S. Is the prevalence of HIV-associated nephropathy decreasing? Am J Nephrol 1999;19:655-9.
11. Winston JA, Klotman ME, Klotman PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 1999;55:1036-40.
12. Martins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African Americans. Am J Med Sci 2002;323:65-71.
13. Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002;61:195-202.
14. Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci 2000;319:320-5.
15. Halevy D, Radhakrishnan J, Appel GB. Racial and socioeconomic factors in glomerular disease. Semin Nephrol 2001;21:403-10.
16. Ray PE, Xu L, Rakusan T, Liu X. A 20-year history of childhood HIV-associated nephropathy. Ped Nephrol 2004;19:1075-92.
17. Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998;352:783-4.
18. Scheurer D. Rapid reversal of renal failure after initiation of HAART: a case report. AIDS Read 2004;14:443-7.
19. Rao TK, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 1987;316:1062-8.
20. Carbone L, D'Agati V, Cheng JT, Appel GB. Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med 1989;87:389-95.
21. Mazbar SA, Schoenfeld PY, Humphreys MH. Renal involvement in patients infected with HIV: experience at San Francisco general hospital. Kidney Int 1990;37(5):1325-32.
22. Bourgoignie JJ, Meneses R, Ortiz C, Jaffe D, Pardo V. The clinical spectrum of renal disease associated with human immunodeficiency virus. Am J Kidney Dis 1988;12:131-7.
23. Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999;34:254-8.
24. Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropalhy. Am J Kidney Dis 1996;28:202-8.
25. Sothinathan R, Briggs WA, Eustace JA. Treatment of HIV-associated nephropathy. AIDS Patient Care STDs 2001;15: 363-71.
26. Abbott KC, Trespalacios FC, Agodoa LY, Ahuja TS. HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS wave 2 study. BMC Nephrol 2003;4:5-7.
27. Laradi A, Mallet A, Beaufils H, Allonache M, Martinez F. HIV-associated nephropathy: outcome and prognosis factors. Groupe d' etudes nephrologiques d'ile de France. J Am Soc Nephrol 1998;9:2327-35.
28. Burns GC, Matute R, Onyema D, Davis I, Toth I. Response to inhibition of angiotensin-converting enzyme in human immunodeficiency virus-associated nephropathy: a case report. Am J Kidney Dis 1994;23:441-3.
29. Burns GC, Paul SK, Toth IR, Sivak SL. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997;8:1140-6.
30. Husain M, Gusella GL, Klotman ME, et al. HIV-1 ne∫ induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 2002;13:1806-15.
31. Ray PE, Liu XH, Henry D, et al. Infection of human primary renal epithelial cells with HIV-1 from children with HIV-associated nephropathy. Kidney Int 1998;53:1217-29.
32. Kitchen SG, Korin YD, Roth MD, Landay A, Zack JA. Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol 1998;72:9054-60.
33. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000;11:2079-87.
34. Mongia A, Bhaskaran M, Reddy K, Manjappa N, Baqi N, Singhal PC. Protcase inhibitors modulate apoptosis in mesangial cells derived from a mouse model of HIVAN. Kidney Int 2004;65:860-70.
35. Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 2002;323:102-6.
36. Szczech LA, Edwards LJ, Sanders LL, et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002;57:336-41.
37. Winston JA, Bruggeman LA, Ross MD, et al. Nephropalhy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001;344:1979-84.
38. Winston JA, Burns GC, Klotman PE. Treatment of HIV-associated nephropathy. Semin Nephrol 2000;20:293-8.
39. Betjes MG, Verhagen DW. Stable improvement of renal function after initiation of highly active anti-retroviral therapy in patients with HIV-1-associated nephropathy. Nephrol Dial Transplant 2002;17:1836-9.
40. Yamamoto T, Noble NA, Miller DE, et al. Increased levels of transforming growth factor-beta in HIV-associated nephropathy. Kidney Int 1999;55:579-92.
41. Russo LM, Brammar GC, Jerums G, Comper WD, Osicka TM. The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth lactor-beta expression. J Hypertens 2003;21:419-28.
42. Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/Nep type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest 2003;83:1267-77.
43. Di Paolo S, Schena A, Stallone G. et al. Captopril enhances transforming growth factor (TGF)-beta 1 expression in peripheral blood mononuclear cells: a mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation 2002;74:1710-15.
44. Klotman PE. HIV-associated nephropathy. Kidney Int 1999;56:1161-76.
45. Lau A. Glomerulonephritis. In: DiPiro JT, Talberl RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotberapy: a pathophysiologic approach. New York: McGraw-Hill Companies, Inc., 2002:911-38.
46. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACE1 to angiotensin 11 antagonists. Kidney Int 2000;57:1803-17.
47. Rao TK. Clinical features of human immunodeficiency virus associated nephropathy. Kidney Int 1991;40(suppl 35):S13-18.
48. Cook PP, Appel RG. Prolonged clinical improvement in HIV-associated nephropathy with zidovudine therapy [letter]. J Am Soc Nephrol 1990;1:842.
49. Ifudu O, Rao TK, Tan CC, Fleischman H, Chirgwin K, Friedman EA. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 1995;15:217-21.
50. Hedayati SS, Reddan DN, Szczech LA. HIV-associated nephropathy: a review of the epidemiology and clinical course in the HAART era. AIDS Patient Care STDs 2003;17:57-63.
51. Wei A, Burns GC, Williams BA, Mohammed NB, Visintainer P, Sivak SL. Long-term renal survival in HIV-associated nephropathy with angiotensin- converting enzyme inhibition. Kidney Int 2003;64:1462-71.
52. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004;18:541-6.
53. Saulsbury F. Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clin Infect Dis 2001;32:464-8.
54. Kirchner JT. Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature. AIDS Read 2002;12:103-5, 110-12.
55. Viani RM, Dankner WM, Muelenaer PA, Spector SA. Resolution of HIV-associated nephrotic syndrome with highly active antiretroviral therapy delivered by gaslrostomy tube. Pediatrics 1999;104:1394-6.
56. Smith MC, Pawar R, Carey JT, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med 1994;97:145-51.
57. Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996;101:41-8.
58. Eustace JA, Nuermberger E, Choi M, Scheel PJ Jr, Moore R, Briggs WA. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000;58:1253-60.
59. Watterson MK, Detwiler RK, Bolin P Jr. Clinical response to prolonged corticosteroids in a patient with human immunodeficiency virus-associated nephropathy. Am J Kidney Dis 1997;29:624-6.
60. Briggs WA, Tanawattanacharoen S, Choi MJ, Scheel PJ Jr, Nadasdy T, Racusen L. Clinicopathologic correlates of prcdnisonc treatment of human immunodeficiency virus-associated nephropathy. Am J Kidney Dis 1996;28:618-21.
61. Tayal SC, Ghosh SK, Reaich D. Asymptomatic HIV patient with cardiomyopathy and nephropathy: case report and literature review. J Infect 2001;42:288-90.
62. Kimmel PL, Bosch JP, Vassalotti JA. Treatment of human immunodeficiency virus (HIV)-associated nephropathy. Semin Nephrol 1998;18:446-58.
63. Betjes MG, Weening J, Krediet RT. Diagnosis and treatment of HIV-associated nephropathy. Neth J Med 2001;59:111-17.
64. Frem GJ, Rennke HG, Sayegh MH. Late renal allograft failure secondary to thrombotic microangiopathy-human immunodeficiency virus nephropathy. J Am Soc Nephrol 1994;4:1643-8.
65. Barllett JG, Lane HC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, 2005. Available from http://aidsinfo.nih.gOv/guidelines/adult/AA_040705.pdf. Accessed May 26, 2005.
66. Foster MH. Taking HAART in HIVAN: will proteasc inhibitor sparing regimens alter renal outcome? Kidney Int 2004;65:1105-6.
67. Rao TK. Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial 2003;16:233-44.
68. Izzedine H, Launay-Vacher V, Deray G. Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis [letter]. Kidney Int 2003;64:2324.
69. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of antiretroviral drugs in hemodialysis. Kidney Int 2001;60:821-30.
70. Ingulli E, Tejani A, Fikrig S, Nicastri A, Chen CK, Pomrantz A. Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 1991;119: 710-16.
71. Rajpoot D, Kaupke CJ, Vaziri ND, Rao TK, Pomrantz A, Fikrig S. Childhood AIDS nephropathy: a 10-year experience. J Natl Med Assoc 1996;88:493-8.
72. Appel RG, Neill J. A steroid-responsive nephrotic syndrome in a patient with human immunodeficiency virus (HIV) infection. Ann Intern Med 1990;113:892-3.
73. National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneunacystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1500-4.
74. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California collaborative treatment group. N Engl J Med 1990;323:1451-7.
75. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial. N Engl J Med 1990;323:1444-50.